# Clinical Cancer Research

## Table of Contents

### Highlights of This Issue 273

#### SPECIAL FEATURES

**CCR Translations**

- **275** Stressing the Development of Small Molecules Targeting HSP90
  Len Neckers and Jane B. Trepel
  See related article, p. 445

- **278** Pertuzumab Protects the Achilles’ Heel of Trastuzumab—Emtansine
  William R. Gwin and Neil L. Spector
  See related article, p. 456

**CCR Perspectives in Drug Approval**

- **281** Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs
  Denis L. Jardim, Kenneth R. Hess, Patricia LoRusso, Razelle Kurzrock, and David S. Hong

**Molecular Pathways**

- **289** Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancer—From Molecular Mechanism to Therapeutic Application
  Simone Fulda

- **296** Molecular Pathways: Transcription Factories and Chromosomal Translocations
  Cameron S. Osborne

**Reviews**

- **301** “Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation
  Benjamin A. Toll, Alana M. Rojewski, Lindsay R. Duncan, Amy E. Latimer-Cheung, Lisa M. Fucito, Julie L. Boyer, Stephanie S. O’Malley, Peter Salovey, and Roy S. Herbst

- **310** Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?
  François-Xavier Mahon and Gabriel Etienne

### HUMAN CANCER BIOLOGY

- **323** IgG-Switched CLL Has a Distinct Immunogenetic Signature from the Common MD Variant: Ontogenetic Implications
  Anna Vardi, Andreas Agathangelidis, Lesley-Ann Sutton, Maria Chatzouli, Lydia Scarfo, Larry Mansouri, Vassiliki Douka, Achilles Anagnostopoulos, Nikos Darzentas, Richard Rosenquist, Paolo Chia, Chrysoula Belessi, and Kostas Stamatis

- **331** Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
  Simon Turcotte, Alena Gros, Eric Tran, Chyi-Chia R. Lee, John R. Wunderlich, Paul F. Robbins, and Steven A. Rosenberg

- **344** Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence

- **358** The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis
  Armelle Luscan, Ghjuvan Ghjacumu Shackleford, Julien Masliah-Planchnon, Ingrid Laurendeau, Nicolas Ortonne, Jennifer Varin, François Lallemand, Karen Leroy, Valérie Dumaine, Mikael Hivelin, Didier Borderie, Thomas De Raedt, Laurence Valeyre-Allanore, Frédéric Larousserie, Benoît Terris, Laurent Lantieri, Michel Vidaud, Dominique Vidaud, Pierre Wolkenstein, Béatrice Parfait, Ivan Bichè, Charbel Massaad, and Eric Pasman

- **372** Oncogenic Function of SCCR05/DCUN1D5 Requires Its Neddylation E3 Activity and Nuclear Localization
  Claire C. Bommelje, Viola B. Weeda, Guochang Huang, Kushyup Shah, Sarina Bains, Elizabeth Buss, Manish Shaha, Mithat Gonen, Ronald Ghossein, Suresh Y. Ramanathan, and Bhuvanesh Singh
CANCER THERAPY: PRECLINICAL

382  Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
      Violetta V. Leshchenko, Pei-Yu Kuo, Zewei Jiang, Venu K. Thirukonda, and Samir Parekh

393  Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes
      Alexandra Moros, Sophie Bustany, Julie Cahu, Ilfigenia Saborit-Villarroya, Antonio Martínez, Dolors Colomer, Brigitte Sola, and Gaël Roué

404  Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
      Evita M. Lindholm, Marit Krohn, Sergio Iadevaia, Alexandr Kristian, Gordon B. Mills, Gunhild M. Mønlandsmo, and Olav Engebraaten

413  Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

IMAGING, DIAGNOSIS, PROGNOSIS

425  Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity
      Alexander Gröbe, Marco Blessmann, Henning Hanken, Reinhard E. Friedrich, Gerhard Schön, Johannes Wilker, Katharina E. Effenberger, Lan Kluwe, Max Heiland, Klaus Pantei, and Sabine Riethdorf

434  Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
      John R. Webb, Katy Milne, Peter Watson, Ronald J. deLeeuw, and Brad H. Nelson

CANCER THERAPY: CLINICAL

445  A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIBO201 Administered Orally in Patients with Advanced Solid Tumors
      Muhammad Wasif Saif, Chris Takimoto, Monica Mita, Udai Banerji, Nicole Lamanna, Januario Castro, Susan O’Brien, Christopher Stogard, and Daniel Van Hoff
      See related article, p. 275

456  Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
      See related article, p. 278

469  The High-Affinity CXCR4 Antagonist BKT140 is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
      Amnon Peled, Michal Abraham, Irit Avivi, Jacob M. Rowe, Katia Beider, Hanna Wald, Lena Tiomkin, Lena Ribakovskiy, Yossi Riback, Yaron Ramati, Sigal Aviel, Ethan Galun, Howard Laurence Shaw, Orly Eizenberg, Izhar Hardan, Avichai Shimoni, and Amon Nagler

480  Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

490  Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up
Selma Ugurel, Thomas Mentzel, Jochen Utikal, Peter Helmbold, Peter Mohr, Claudia Pfoehler, Meinhard Schiller, Axel Hauschild, Rüdiger Hein, Eckhardt Käppgen, Ivonne Kellner, Martin Leverkus, Jürgen C. Becker, Philip Ströbel, and Dirk Schadendorf

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat, Giampaolo Bianchini, Marlene Thomas, Anton Belousov, Maggie C.U. Cheang, Astrid Koepler, Patricia Gómez, Vladimir Semiglazov, Wolfgang Eiermann, Sergei Tjulandin, Mikhail Byakhow, Begoña Bermejo, Milvia Zambetti, Federico Vazquez, Luca Gianni, and José Baselga

The cover shows a section of a lymph node biopsy from a patient with mantle cell lymphoma. Hematoxylin and eosin staining shows typical monomorphous small-to-medium-sized lymphoid cells with irregular nuclei. For details, see the article by Moros and colleagues on page 393 of this issue.